Milprazon Chewable (5 - 25 kg)
ATC code
Species
Dogs (weighing at least 5 kg).
Indications
Treatment of mixed infections by adult cestodes and nematodes of the following species:
- Cestodes: Dipylidium caninum Taenia spp.
Echinococcus spp.
Mesocestoides spp.
- Nematodes:
Ancylostoma caninum
Toxocara canis
Toxascaris leonina
Trichuris vulpis
Crenosoma vulpis (Reduction of the level of infection)
Angiostrongylus vasorum (Reduction of the level of infection by immature adult (L5) and adult parasite stages; see specific treatment and disease prevention schedules under section 4.9 Amounts to be administered and administration route)
Thelazia callipaeda (see specific treatment schedule under section 4.9 Amounts to be administered and administration route)
The product can also be used in the prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.
Dose to be administered and administration route
Oral use.
Dogs should be weighed to ensure accurate dosing.
Minimum recommended dose rate: 0.5 mg of milbemycin oxime and 5 mg of praziquantel per kg are given once orally.
The product should be administered with or after some food. The product is palatable i.e. it is usually taken voluntarily by dogs (voluntary consumption on > 80% of occasions in animals studied). If the dog does not voluntarily accept the tablet, it can also be administered into the mouth.
Depending on the bodyweight of the dog, the practical dosing is as follows:
Body weight | Film-coated tablets |
5 – 25 kg | 1 tablet |
>25 – 50 kg | 2 tablets |
>50 – 75 kg | 3 tablets |
In cases when heartworm disease prevention is used and at the same time treatment against tapeworm is required, the product can replace the monosubstance product for the prevention of heartworm disease.
For treatment of Angiostrongylus vasorum infections, milbemycin oxime should be given four times at weekly intervals. It is recommended, where concomitant treatment against cestodes is indicated, to treat once with the product and continue with the monovalent product containing milbemycin oxime alone, for the remaining three weekly treatments.
In endemic areas administration of the product every four weeks will prevent angiostrongylosis by reducing immature adult (L5) and adult parasite burden, where concomitant treatment against cestodes is indicated.
For the treatment of Thelazia callipaeda, milbemycin oxime should be given in 2 treatments, seven days apart. Where concomitant treatment against cestodes is indicated, the product can replace the monosubstance product containing milbemycin oxime alone.
Adverse reactions
On very rare occasions, systemic signs (such as lethargy), neurological signs (such as muscle tremors and ataxia) and/or gastrointestinal signs (such as emesis, diarrhoea, anorexia and drooling) have been observed in dogs after administration of the combination of milbemycin oxime and praziquantel.
On very rare occasions hypersensitivity reactions have been observed following administration of the product.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Dispensing
POM-VSimilar products
Showing 3 of 3 results
Milprazon Chewable (5 - 25 kg)
Milprazon Chewable (5 - 25 kg)
